期刊文献+

正交试验优化盐酸帕洛诺司琼口腔崩解片的制备工艺

Preparation optimization of palonosetron hydrochloride oral disintegrating tablets by orthogonal test
下载PDF
导出
摘要 目的研究并优化盐酸帕洛诺司琼口腔崩解片的制备工艺。方法采用粉末直接压片法制备盐酸帕洛诺司琼口腔崩解片,采用HPLC法测定其含量,以崩解时限为指标优化处方。结果以12%低取代羟丙甲基纤维素,甘露醇∶优化微晶纤维素为2∶1,2%硬脂酸镁,3%甜菊苷制备的盐酸帕洛诺司琼口腔崩解片(60mg/片)外观圆整光洁,口感良好,崩解时限为12s,硬度为3kg,4min溶出度为99%。结论该制剂制备简单,处方合理,崩解较快。 Objective To prepare optimization of palonosetron hydrochloride oral disintegrating tablets by orthogonal test. Methods Palonosetron hydrochloride oral disintegrating tablets were prepared with direct compression process. The content of pal- onosetron hydrochloride was determined by HPLC. The formulation was optimized with disintegration time as evaluation indices. Results The optimal formulation(60 rag/tablet) was as follows:L-HPC 12% ,mannitol . SMCC= 2 : 1,magnesium stearate 2%, stevia glycosides 3 %. The oral disintegrating tablets showed dine appearance and tested better: the disintegration time was 12 sec- onds;the tablets featured a hardness of 3 kg;4 min dissolution rate was 99%. Conclusion The preparation method is simple and reasonable,and the tablets can disintegrate rapidly.
出处 《重庆医学》 CAS 北大核心 2015年第24期3393-3395,共3页 Chongqing medicine
关键词 处方 药物 药用制剂 盐酸帕洛诺司琼 口腔崩解片 直接压片法 崩解时间 溶出度 prescriptions, drug pharmaceutical preparations palonosetron hydrochloride orally disintegrating tablets directcompression process disintegration time clissolution
  • 相关文献

参考文献14

  • 1Rubenstein EB. Palonosetron: a unique 5-HT3 receptorantagonist indicated for the prevention of acute and de-layed chemotherapy-induced nausea and vomiting[J]. ClinAdv Hematol Oncol,2004,2(5) :284-289.
  • 2Navari RM. Palonosetron for the treatment of chemother-apy-induced nausea and vomiting[J]. Expert Opin Phar-macother,2014,15(17) :2599-2608.
  • 3Affronti ML, Bubalo J. Palonosetron in the managementof chemotherapy-induced nausea and vomiting in patientsreceiving multiple-day chemotherapy [J ]. Cancer ManagRes,2014,6(6):329-337.
  • 4Navari RM. Profile of netupitant/palonosetron (NEPA)fixed dose combination and its potential in the treatmentof chemotherapy-induced nausea and vomiting (CINV)[J], Drug Des Devel Ther,2015,9(9) : 155-161.
  • 5Evren AY. Orally disintegrating tablets:an overview[J]. JAppl Pharm Sci,2014,4(2) :118-125.
  • 6Dharwal DJ, Shukla DS. Pandey DR, et al. Orally disinte-grating tablets: a complete review on methodology [J]. A-sian J Res Pharm Sci,2013 ,3(4) *161-169.
  • 7史香龄,邵方娴,宋敏,杭太俊,杨林,文爱东,张喜全,戴峻,王艳霞,李琨.盐酸帕洛诺司琼胶囊的人体药动学及绝对生物利用度[J].中国新药杂志,2013,22(6):681-685. 被引量:3
  • 8国家食品药品监督管理局审评四部药学组.口腔崩解片的剂型特点和质量控制会议纪要[EB/OL]. (2003-08-02) [2013-12—15] .http : //www.chinabaike.com/z/yiqi/2011/0327/634443.html.
  • 9巫传玲,于波涛,范开华.盐酸异丙嗪口崩片的制备[J].华西药学杂志,2013,28(2):129-131. 被引量:3
  • 10Zhao HY,Li GP, Wu JF,et al. HPLC separation and de-termination of three optical isomers of palonosetronhydrochloride[J]. Chin J Pharm Anal,2012,32 ( 6) : 978-980.

二级参考文献17

  • 1王海凤,王东凯.5-HT_3受体阻滞剂帕洛诺司琼[J].中国新药杂志,2006,15(10):833-835. 被引量:16
  • 2Rubenstein EB. Palonosetron:A unique 5 - HT(3) receptor antagonist indicated for the prevention of acute and delayed chemotherapy - induced nausea and vomiting. Clin Adv Hematol Oncol,2004,2 (5) : 284.
  • 3沈曦,周慧,王万青,蔡华芳.反相高效液相色谱法检测盐酸帕洛诺司琼及其有关物质[J].中国现代应用药学,2007,24(4):307-308. 被引量:4
  • 4ChP(中国药典).2005.Vol Ⅱ(二部):730
  • 5SEPULVEDA-VILD6SOLA AC,BETANZOS-CABRERA Y,LA*STIKI GG,et al. Palonosetron hydrochloride is an effective andsafe option to prevent chemotherapy-induced nausea and vomitingin children[ J]. Arch Med Res,2008,39(6) :601 -606.
  • 6US Food and Drug Administration. Palonosetron [ EB/OL].[2011 -07 - 18], http://www. fda. gov/cder/foi/label/2003/21372_aloxi_lbl. pdf.
  • 7HUNT TL,GALLAGHER SC,CULLEN MT JR,et al. Evaluationof safety and pharmacokinetics of consecutive multiple-day dosingof palonosetron in healthy subjects[ J]. Clin Pharmacol,2005 ,45(5):589 -596.
  • 8STOLTZ R , CYONG JC , SHAH A ,et al. Pharmacokinetic andsafety evaluation of palonosetron,a 5 -hydroxytryptamine-3 recep-tor antagonist, in U. S. and Japanese healthy subjects [ J ]. ClinPharmacol,2004 44(5) :520 -531.
  • 9US Food and Drug Administration. Guidance for industry:bioana-lytical method validation[ EB/OL]. [2011 - 09 - 10]. http://www. fda. gov/downloads/Drugs/GuidanceComplianceRegulatory-Information/Guidances/UCM070107. pdf.
  • 10VISHNU MURTHY M.SRINIVAS K,KUMAR R,e( al. Develop-ment and validation of a stability-indicating LC method for deter-mining palonosetron hydrochloride,its related compounds anddegradation products using naphthalethyl stationary phase [ J ]. JPharm Biomed Anal,2011,56(2) :429 -435.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部